Identification of Ligand-Receptor Pairs Associated With Tumour Characteristics in Clear Cell Renal Cell Carcinoma
(1) Liu F (2) Wang P (3) Sun W (4) Jiang Y (5) Gong Q
The role of IL-33/ST2 signaling in the tumor microenvironment and Treg immunotherapy
(1) Lei S (2) Jin J (3) Zhao X (4) Zhou L (5) Qi G (6) Yang J
(1) Lei S (2) Jin J (3) Zhao X (4) Zhou L (5) Qi G (6) Yang J
Author Info: (1) Department of Immunology, Guilin Medical University, Guilin 541199, Guangxi, China. Department of Pathophysiology, Guilin Medical University, Guilin 541199, Guangxi, China. Gua
Author Info: (1) Department of Immunology, Guilin Medical University, Guilin 541199, Guangxi, China. Department of Pathophysiology, Guilin Medical University, Guilin 541199, Guangxi, China. Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541199, Guangxi, China. (2) Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541199, Guangxi, China. (3) Department of Immunology, Guilin Medical University, Guilin 541199, Guangxi, China. (4) Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541199, Guangxi, China. (5) Department of Pathophysiology, Guilin Medical University, Guilin 541199, Guangxi, China. Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541199, Guangxi, China. (6) Department of Immunology, Guilin Medical University, Guilin 541199, Guangxi, China. Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541199, Guangxi, China.
Citation: Exp Biol Med (Maywood) 2022 Jun 22 15353702221102094 Epub06/22/2022
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35733343
Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control
(1) Tondini E (2) Reintjens NRM (3) Castello G (4) Arakelian T (5) Isendoorn M (6) Camps M (7) Vree J (8) van der Marel GA (9) Filippov DV (10) Codee JDC (11) Ossendorp F
(1) Tondini E (2) Reintjens NRM (3) Castello G (4) Arakelian T (5) Isendoorn M (6) Camps M (7) Vree J (8) van der Marel GA (9) Filippov DV (10) Codee JDC (11) Ossendorp F
Author Info: (1) Department of Immunology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. (2) Bio-organic Synthesis, Leiden Institute of
Author Info: (1) Department of Immunology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. (2) Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333, CC, Leiden, The Netherlands. (3) Department of Immunology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. (4) Department of Immunology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. (5) Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333, CC, Leiden, The Netherlands. (6) Department of Immunology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. (7) Department of Immunology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. (8) Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333, CC, Leiden, The Netherlands. (9) Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333, CC, Leiden, The Netherlands. (10) Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333, CC, Leiden, The Netherlands. jcodee@chem.leidenuniv.nl. (11) Department of Immunology, Leiden University Medical Center, Leiden University, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. f.a.ossendorp@lumc.nl.
Citation: NPJ Vaccines 2022 Jun 23 7:64 Epub06/23/2022
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35739113
A degron system targeting endogenous PD-1 inhibits the growth of tumor cells in mice
(1) Naruse C (2) Sugihara K (3) Miyazaki T (4) Pan X (5) Sugiyama F (6) Asano M
(1) Naruse C (2) Sugihara K (3) Miyazaki T (4) Pan X (5) Sugiyama F (6) Asano M
Author Info: (1) Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. (2) Institute of Laboratory Animals, Graduat
Author Info: (1) Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. (2) Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. (3) Department of Pathology, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1104, Japan. (4) Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. (5) Laboratory Animal Resource Center, Transborder Medical Research Center, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. (6) Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.
Citation: NAR Cancer 2022 Jun 4:zcac019 Epub06/17/2022
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35734392
Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma
(1) du Chatinier A (2) Meel MH (3) Das AI (4) Metselaar DS (5) Waranecki P (6) Bugiani M (7) Breur M (8) Simonds EF (9) Lu ED (10) Weiss WA (11) Garcia Vallejo JJ (12) Hoving EW (13) Phoenix TN (14) Hulleman E
(1) du Chatinier A (2) Meel MH (3) Das AI (4) Metselaar DS (5) Waranecki P (6) Bugiani M (7) Breur M (8) Simonds EF (9) Lu ED (10) Weiss WA (11) Garcia Vallejo JJ (12) Hoving EW (13) Phoenix TN (14) Hulleman E
Author Info: (1) Princess Mxima Center for Pediatric Oncology, Utrecht, the Netherlands. (2) Princess Mxima Center for Pediatric Oncology, Utrecht, the Netherlands. (3) Princess Mxima Center
Author Info: (1) Princess Mxima Center for Pediatric Oncology, Utrecht, the Netherlands. (2) Princess Mxima Center for Pediatric Oncology, Utrecht, the Netherlands. (3) Princess Mxima Center for Pediatric Oncology, Utrecht, the Netherlands. (4) Princess Mxima Center for Pediatric Oncology, Utrecht, the Netherlands. (5) Princess Mxima Center for Pediatric Oncology, Utrecht, the Netherlands. (6) Department of Pathology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. (7) Department of Pathology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. (8) Departments of Neurology, Neurological Surgery, and Pediatrics, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA. (9) Departments of Neurology, Neurological Surgery, and Pediatrics, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA. (10) Departments of Neurology, Neurological Surgery, and Pediatrics, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA. (11) Department of Molecular Cell Biology and Immunology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. (12) Princess Mxima Center for Pediatric Oncology, Utrecht, the Netherlands. (13) Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati/Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. (14) Princess Mxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Citation: Neurooncol Adv 2022 Jan-Dec 4:vdac079 Epub05/24/2022
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35733514
Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
(1) Buonato JM (2) Edwards JP (3) Zaritskaya L (4) Witter AR (5) Gupta A (6) LaFleur DW (7) Tice DA (8) Richman LK (9) Hilbert DM
(1) Buonato JM (2) Edwards JP (3) Zaritskaya L (4) Witter AR (5) Gupta A (6) LaFleur DW (7) Tice DA (8) Richman LK (9) Hilbert DM
Citation: Mol Cancer Ther 2022 Jun 23 OF1-OF13 Epub06/23/2022
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35737298
Activation of cytotoxic T lymphocytes by self-differentiated myeloid-derived dendritic cells for killing breast cancer cells expressing folate receptor alpha protein
(1) Luangwattananun P (2) Chiraphapphaiboon W (3) Thuwajit C (4) Junking M (5) Yenchitsomanus PT
(1) Luangwattananun P (2) Chiraphapphaiboon W (3) Thuwajit C (4) Junking M (5) Yenchitsomanus PT
Author Info: (1) Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Division of Molecular
Author Info: (1) Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol, University, Bangkok, Thailand. (2) Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol, University, Bangkok, Thailand. (3) Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. (4) Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol, University, Bangkok, Thailand. (5) Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol, University, Bangkok, Thailand.
Citation: Bioengineered 2022 Jun 13:14188-14203 Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35734827
Generation of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer
(1) Prommersberger S (2) Monjezi R (3) Botezatu L (4) Miskey C (5) Amberger M (6) Mestermann K (7) Hudecek M (8) Ivics Z
(1) Prommersberger S (2) Monjezi R (3) Botezatu L (4) Miskey C (5) Amberger M (6) Mestermann K (7) Hudecek M (8) Ivics Z
Author Info: (1) Department of Internal Medicine II, University Hospital of Wrzburg, Wrzburg, Germany. (2) Department of Internal Medicine II, University Hospital of Wrzburg, Wrzburg, Germa
Author Info: (1) Department of Internal Medicine II, University Hospital of Wrzburg, Wrzburg, Germany. (2) Department of Internal Medicine II, University Hospital of Wrzburg, Wrzburg, Germany. (3) Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany. (4) Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany. (5) Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany. (6) Department of Internal Medicine II, University Hospital of Wrzburg, Wrzburg, Germany. (7) Department of Internal Medicine II, University Hospital of Wrzburg, Wrzburg, Germany. (8) Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany. zoltan.ivics@pei.de.
Citation: Methods Mol Biol 2022 2521:41-66 Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35732992
Tags:
Vaccines for immunoprevention of DNA mismatch repair deficient cancers
(1) Hernandez-Sanchez A (2) Grossman M (3) Yeung K (4) Sei SS (5) Lipkin S (6) Kloor M
(1) Hernandez-Sanchez A (2) Grossman M (3) Yeung K (4) Sei SS (5) Lipkin S (6) Kloor M
Author Info: (1) Department of Applied Tumor Biology, University Hospital Heidelberg Institute of Pathology, Heidelberg, Germany. (2) Department of Medicine, Weill Cornell Medicine, New York, N
Author Info: (1) Department of Applied Tumor Biology, University Hospital Heidelberg Institute of Pathology, Heidelberg, Germany. (2) Department of Medicine, Weill Cornell Medicine, New York, New York, USA. (3) Department of Medicine, Weill Cornell Medicine, New York, New York, USA. (4) Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA. (5) Department of Medicine, Weill Cornell Medicine, New York, New York, USA stl2012@med.cornell.edu. (6) University Hospital Heidelberg, Institute of Pathology, Department of Applied Tumor Biology, Heidelberg, Germany.
Citation: J Immunother Cancer 2022 Jun 10: Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35732349
Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model
(1) Nguyen-Hoai T (2) Hohn O (3) Pezzutto A (4) Westermann J
(1) Nguyen-Hoai T (2) Hohn O (3) Pezzutto A (4) Westermann J
Author Info: (1) Experimental and Clinical Research Center, Charit - Universittsmedizin Berlin, Berlin, Germany. hoai-tam.nguyen@charite.de. (2) Robert Koch Institute, Berlin, Germany. (3) Ch
Author Info: (1) Experimental and Clinical Research Center, Charit - Universittsmedizin Berlin, Berlin, Germany. hoai-tam.nguyen@charite.de. (2) Robert Koch Institute, Berlin, Germany. (3) Charit - Universittsmedizin Berlin and Max-Delbrck-Center for Molecular Medicine, Berlin, Germany. (4) Department Hematology, Oncology and Immunology, Charit - Universittsmedizin Berlin, Berlin, Germany.
Citation: Methods Mol Biol 2022 2521:129-154 Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/35732996